Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 mars 2026 02h00 HE | Source: Pharming Group N.V.

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

Pharming announces positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
24 mars 2026 02h00 HE | Source: Pharming Group N.V.

Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients...
06 nov. 2025 01h00 HE | Source: Pharming Group N.V.

Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

Pharming Group reports Q3 2025 results with significant growth in revenue, profit, and cash flow driven by rare disease portfolio performance.